Cosmos Health CEO granted 2.35M common shares

Cosmos Health Inc. Director and Chief Executive Officer Grigorios Siokas received an equity compensation award that converted restricted stock units into common shares.

Rhea-AI Filing Summary

Cosmos Health Inc. Director and Chief Executive Officer Grigorios Siokas received an equity compensation award that converted restricted stock units into common shares. On May 19, 2026, 2,350,000 restricted stock units granted under the company’s 2024 & 2025 Omnibus Incentive Plan vested and were converted into 2,350,000 shares of common stock at a stated value of $0.283 per share.

Following this grant and conversion, Siokas directly owns 12,561,914 shares of Cosmos Health common stock. The filing notes that these transactions were made under the company’s omnibus incentive plan and are exempt under Rule 16b-3, indicating they are compensation-related awards rather than open-market purchases or sales.

Insider Trade Summary

2,350,000 shares exercised/converted

Exercise 2 txns

Insider Siokas Grigorios

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Conversion	Restricted Stock Unit	2,350,000	$0.00	$0.00
Grant/Award	Common Stock, par value $.001	2,350,000	$0.283	$665K

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock, par value $.001 — 12,561,914 shares (Direct)

Footnotes (2)

1. F1. Reflects the award of 2,350,000 shares of common stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.
2. F2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

Key Figures

Shares acquired via RSU conversion: 2,350,000 shares Stated value per share: $0.283 per share Post-transaction holdings: 12,561,914 shares +2 more

5 metrics

Shares acquired via RSU conversion 2,350,000 shares Restricted stock units vested and converted on May 19, 2026

Stated value per share $0.283 per share Common stock grant value for 2,350,000 shares

Post-transaction holdings 12,561,914 shares Common stock directly owned after the award

RSUs converted 2,350,000 units Restricted Stock Units converted into common stock

Rule 16b-3 exemption Yes Grant and vesting exempt as compensation-related insider transactions

Key Terms

Restricted Stock Unit, Omnibus Incentive Plan, Rule 16b-3, Grant, award, or other acquisition, +1 more

5 terms

Restricted Stock Unit financial

"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Omnibus Incentive Plan financial

"pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Conversion of derivative security financial

"transaction_code_description: Conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cosmos Health (COSM) disclose in this Form 4 for Grigorios Siokas?

Cosmos Health disclosed that CEO and director Grigorios Siokas received equity compensation. 2,350,000 restricted stock units vested and converted into common stock under the 2024 & 2025 Omnibus Incentive Plan, increasing his direct holdings to 12,561,914 shares.

How many Cosmos Health shares did Grigorios Siokas acquire in this transaction?

Grigorios Siokas acquired 2,350,000 shares of Cosmos Health common stock. These came from restricted stock units that vested and converted on May 19, 2026, under the company’s 2024 & 2025 Omnibus Incentive Plan as part of his compensation.

Is the Cosmos Health (COSM) Form 4 a market purchase or a compensation grant?

The Form 4 reflects a compensation grant, not a market purchase. Restricted stock units granted under the 2024 & 2025 Omnibus Incentive Plan vested into 2,350,000 common shares in a transaction exempt under Rule 16b-3, indicating a planned equity award.

What are restricted stock units (RSUs) in the Cosmos Health Form 4?

In this filing, restricted stock units are compensation rights that convert into common shares. Siokas’s RSUs, granted under the 2024 & 2025 Omnibus Incentive Plan, vested on May 19, 2026 and converted into 2,350,000 Cosmos Health common shares at that time.

How many Cosmos Health shares does Grigorios Siokas hold after this Form 4 event?

After the RSU conversion, Grigorios Siokas holds 12,561,914 Cosmos Health common shares directly. This total reflects the addition of 2,350,000 shares received when his restricted stock units vested and converted under the company’s omnibus incentive plan.

Under what plan and rule were the Cosmos Health RSU awards granted to Siokas?

The RSU awards were granted under Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan. The filing states the grant and vesting transactions are exempt under Rule 16b-3, which typically applies to board-approved, compensation-related awards to insiders like directors and officers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siokas Grigorios

(Last) (First) (Middle)

5 AG. GEORGIOU STR.

(Street)

PILEA THESSALONIKI TK57001

(City) (State) (Zip)

GREECE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $.001	05/19/2026	05/19/2026	A(1)		2,350,000	A	$0.283	12,561,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	05/19/2026	05/19/2026	C			2,350,000	05/19/2026	05/19/2036	Common Stock, par value $.001	2,350,000	$0	0	D

Explanation of Responses:

1. Reflects the award of 2,350,000 shares of common stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.

2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

	/s/ Grigorios Siokas	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)